Physician profile
Michael O Measom
NPI 1861479701
$2,174,250.92
in general payments reported to CMS, 2019-2025
28 companies · $348K in 2025
The $348K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406K · 2020: $132K · 2021: $258K · 2022: $319K · 2023: $335K · 2024: $376K · 2025: $348K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $682K · Consulting Fee: $149K · Travel and Lodging: $132K · Honoraria: $73K · Food and Beverage: $24K · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $682,068.75 |
| Consulting Fee | $148,914.93 |
| Travel and Lodging | $131,939.88 |
| Honoraria | $72,826.50 |
| Food and Beverage | $23,870.92 |
| Education | $134.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $620,197.01 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $507,145.62 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Neurocrine Biosciences, INC. | $380,248.97 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $176,068.95 | 2022-2025 | Auvelity, Sunosi |
| Abbvie INC. | $122,710.75 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $103,925.23 | 2019-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $82,051.40 | 2019-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $76,483.95 | 2019-2024 | Uzedy, Austedo, Austedo Xr |
| Eisai INC. | $22,579.56 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $21,220.80 | 2023-2024 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13,410.53 | 2019-2025 | Abilify Mycite, Abilify Asimtufii, Rexulti |
| Allergan, INC. | $12,785.29 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11,155.95 | 2019-2024 | Trintellix |
| H. Lundbeck A S | $10,848.78 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $6,073.49 | 2020-2025 | Caplyta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $1,784.24 | 2022 | |
| Lundbeck LLC | $1,546.90 | 2019-2024 | Abilify Maintena |
| Indivior INC. | $1,534.80 | 2019-2023 | Perseris |
| Sunovion Pharmaceuticals INC. | $1,164.42 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.71 | 2023-2025 | Ofev |
| Janssen Scientific Affairs, LLC | $363.36 | 2019-2025 | Invega Sustenna |
| Sage Therapeutics, LLC | $202.11 | 2021-2022 | |
| Bioxcel Therapeutics, INC. | $125.00 | 2023 | Igalmi |
| Biogen, INC. | $94.52 | 2022 | |
| Braeburn INC. | $78.80 | 2024 | Brixadi |
| Nevro Corp. | $33.79 | 2023 | Senza |
| Supernus Pharmaceuticals, INC. | $30.66 | 2024 | Qelbree |
| Neuronetics, INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Measom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.